Craig Sauter, MD

Craig Sauter, MD, discusses important considerations regarding the use of pembrolizumab after autologous stem cell transplant in T-cell non-Hodgkin lymphoma.

Craig Sauter, MD, discusses the investigation of pembrolizumab given after stem cell transplant in T-cell non-Hodgkin lymphoma.

Craig Sauter, MD, and Brian T. Hill, MD, PhD, consider CAR T-cell therapy in the second-line setting for patients with diffuse large B-cell lymphoma.

Craig Sauter, MD, and Brian T. Hill, MD, PhD, discuss recent data showing that the CAR T-cell production can be shortened.

Craig Sauter, MD, and Brian T. Hill, MD, PhD, discuss potential directions for CAR T-cell therapy in lymphomas.

Brian T. Hill, MD, PhD, and Craig Sauter, MD, discuss the promise of allogeneic CAR T-cell products.

Craig Sauter, MD, and Brian T. Hill, MD, PhD, address the issue of financial toxicity in CAR T-cell therapy.

Craig Sauter, MD, discusses the differences between off-the-shelf and autologous chimeric antigen receptor T-cell products in patients with hematologic malignancies.

Craig Sauter, MD, discusses the anecdotal observational data in real-world patients with hematologic malignancies who received chimeric antigen receptor T-cell therapy.